title: Cefaclor in the treatment of infective exacerbations of chronic bronchitis in cigarette smokers.
abstract: There is a direct correlation between number of cigarettes smoked and the incidence of lower respiratory tract infection in humans. In studies with smokers suffering from exacerbations of chronic bronchitis, the most common bacterial pathogens found were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Branhamella catarrhalis. Antibiotics should be effective against such possible pathogens. Cefaclor has demonstrated in vitro activity against all these pathogens. We designed the present study to evaluate the efficacy and safety of cefaclor in the treatment of acute exacerbations of chronic bronchitis in cigarette smokers. A total of 106 patients were enrolled in the study. H. influenzae was the most common bacterial species isolated in the sputum (in 23.6% of the total sample), followed by S. pneumoniae (18.9%), S. aureus (17.0%), K. pneumoniae (7.5%) and B. catarrhalis (5.7%), while mixed forms were present in 22.6% of cases and other pathogens in 4.7%. Cefaclor (500 mg) was given orally every 8h for 7 to 16 days (mean 10.73 +/- 2.11). Analysis of clinical response data indicates that 75.5% of patients were cured and 17.0% improved. This finding is important because it demonstrates that cefaclor's spectrum of activity encompasses all the most likely pathogens encountered in smokers. Because of its excellent response rate, cefaclor is of particular value in the treatment of lower respiratory tract infections in cigarette smokers.
authors.affiliation: 36th Division of Pneumology and Respiratory Allergy, A. Cardarelli Hospital, Naples, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Cazzola
authors.forename: C
authors.initials: C
authors.lastname: Franco
authors.forename: V
authors.initials: V
authors.lastname: Gioia
authors.forename: D
authors.initials: D
authors.lastname: Legnani
authors.forename: V
authors.initials: V
authors.lastname: Mancini
authors.forename: M
authors.initials: M
authors.lastname: Polverino
authors.forename: G
authors.initials: G
authors.lastname: Sevieri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002433:Cefaclor / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D016870:Neisseriaceae Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000382:microbiology; D012907:Smoking / Q000009:adverse effects*; D013183:Sputum / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy
chemical_list: D002433:Cefaclor